1. Anti-infection
    Metabolic Enzyme/Protease
  2. HIV
    HIV Protease

Saquinavir (Synonyms: Ro 31-8959)

Cat. No.: HY-17007 Purity: 99.71%
Data Sheet SDS Handling Instructions

Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy.

For research use only. We do not sell to patients.
Saquinavir Chemical Structure

Saquinavir Chemical Structure

CAS No. : 127779-20-8

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $61 In-stock
10 mg $55 In-stock
50 mg $210 In-stock
100 mg $330 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other Forms of Saquinavir:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. IC50 Value: Target: HIV Protease Saquinavir is a protease inhibitor. Proteases are enzymes that cleave protein molecules into smaller fragments. HIV protease is vital for both viral replication within the cell and release of mature viral particles from an infected cell. Saquinavir binds to the active site of the viral protease and prevents cleavage of viral polyproteins, preventing maturation of the virus. Saquinavir inhibits both HIV-1 and HIV-2 proteases.Studies have also looked at Saquinavir as a possible anti-cancer agent.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00622141 The HIV Netherlands Australia Thailand Research Collaboration|The Government Pharmaceutical Organization HIV Infections Phase 1|Phase 2
NCT00379405 Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA HIV Infections June 2006 Phase 4
NCT00438152 Royal Free Hampstead NHS Trust|Roche Pharma AG HIV Infections September 2006 Phase 4
NCT00192608 Kirby Institute|Hoffmann-La Roche HIV Infections November 2004
NCT00002425 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 4
NCT00002383 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 1
NCT00002382 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 3
NCT02184286 Boehringer Ingelheim HIV Infections May 1999 Phase 1
NCT00476983 The HIV Netherlands Australia Thailand Research Collaboration Saquinavir/Ritonavir BID or Lopinavir/Ritonavir BID Phase 2|Phase 3
NCT00002229 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 4
NCT00435929 Hoffmann-La Roche HIV Infections September 2006 Phase 1
NCT00105079 Hoffmann-La Roche HIV Infections April 2005 Phase 3
NCT00389402 International Antiviral Therapy Evaluation Center|Hoffmann-La Roche|Gilead Sciences HIV Infections July 2006 Phase 4
NCT00622206 The HIV Netherlands Australia Thailand Research Collaboration HIV Infections January 2008 Phase 1|Phase 2
NCT00145561 Radboud University|Hoffmann-La Roche HIV Infections August 2005 Phase 1|Phase 2
NCT00000848 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00002111 Stanford University|NIH AIDS Clinical Trials Information Service HIV Infections Phase 1
NCT00002333 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00002380 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 1
NCT00084058 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections Phase 1|Phase 2
NCT00623597 Hoffmann-La Roche HIV Infections June 2008 Phase 2
NCT00000913 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00476359 The HIV Netherlands Australia Thailand Research Collaboration|Roche for trial and Saquinavir,and Abbott for Kaletra HIV Infections October 2003 Phase 4
NCT00002190 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00000898 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00002367 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 3
NCT00038519 Abbott HIV Infections April 2001 Phase 2|Phase 3
NCT01638650 Hoffmann-La Roche HIV Infections January 2012 Phase 1
NCT00050180 National Institutes of Health Clinical Center (CC) Healthy|HIV Infections November 22, 2002 Phase 4
NCT00002374 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 3
NCT00400738 The HIV Netherlands Australia Thailand Research Collaboration|Roche Pharma AG|International Antiviral Therapy Evaluation Center|Kirby Institute HIV Infections March 2004 Phase 2
NCT00043953 Abbott HIV Infections August 2002 Phase 2
NCT00002397 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections|AIDS-Associated Nephropathy Phase 3
NCT00038532 Abbott HIV Infections April 2001 Phase 2
NCT00000920 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections|Pregnancy Phase 1
NCT00035932 Bristol-Myers Squibb HIV Infections November 2001 Phase 3
NCT00477048 The HIV Netherlands Australia Thailand Research Collaboration|Roche Pharma AG|Ministry of Health, Thailand IDV Associated Nephrotoxicity May 2004 Phase 2
NCT00002162 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00001094 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT02239835 Boehringer Ingelheim HIV Infections December 1999 Phase 2
NCT00001040 Hoffmann-La Roche|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00002378 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 3
NCT00002178 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 3
NCT00002347 Parexel|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00002334 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 3
NCT02023450 The Third Xiangya Hospital of Central South University|Xiangya Hospital of Central South University Pulmonary Arterial Hypertension December 2013 Early Phase 1
NCT00122603 French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb|GlaxoSmithKline|Hoffmann-La Roche HIV Infections December 2005 Phase 2
NCT00056641 Boehringer Ingelheim HIV Infections January 2003 Phase 2
NCT00002448 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections October 1999 Phase 3
NCT00002447 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections October 1999 Phase 3
NCT00000892 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00002372 Glaxo Wellcome|NIH AIDS Clinical Trials Information Service HIV Infections Phase 1
NCT00000906 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 1
NCT00005762 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections March 2001
NCT00000941 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 1
NCT00002184 Gilead Sciences|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00001087 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00004584 Bristol-Myers Squibb HIV Infections December 1999 Phase 2
NCT00051831 National Institute of Allergy and Infectious Diseases (NIAID)|AIDS Clinical Trials Group HIV Infections October 2003
NCT00001108 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections Phase 1
NCT00717067 ViiV Healthcare|Pfizer Human Immunodeficiency Virus (HIV) Infection July 2008 Phase 4
NCT00476606 The HIV Netherlands Australia Thailand Research Collaboration|Khon Kaen University HIV Infections March 2003
NCT00307502 Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA HIV Infections January 2005 Phase 1
NCT00046033 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00003008 Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|AIDS Associated Malignancies Clinical Trials Consortium Sarcoma June 1997 Phase 2
NCT00002440 Glaxo Wellcome|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00000891 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00102206 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections Phase 2
NCT00000918 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00192660 Kirby Institute|St Vincent's Hospital, Sydney|National Heart, Lung, and Blood Institute (NHLBI) HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease February 2003 Phase 4
NCT00000912 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
View MoreCollapse
References
M.Wt

670.84

Formula

C₃₈H₅₀N₆O₅

CAS No.

127779-20-8

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.71%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Saquinavir
Cat. No.:
HY-17007
Quantity: